Nextleaf Solutions Ltd. (“Nextleaf”, “OILS”, or the “Company”) (CSE:OILS, OTCQB:OILFF, FSE:L0MA) announced today it has completed the acquisition of intellectual property pertaining to the nano delivery of cannabinoids, including the foundational processing methodology and two water soluble formulations (the “Acquired IP”). The initial agreement to purchase the Acquired IP was announced on September 23, 2019.

Ten years of R&D has resulted in a proprietary delivery system that has been adapted to cannabis, increasing bioavailability through nanoemulsification to deliver rapid onset of THC, CBD, and other cannabinoids.


Nextleaf believes the critical driver for the success of cannabis-infused drinks and edibles involves onset time — how long it takes for the consumer to feel the desired effect from the product.

“The intellectual property we’ve acquired allows consumers to feel the desired effect from cannabinoid infused drinks and edibles in under 10 minutes. We are excited to commercialize this game changing technology by supplying water-soluble THC and CBD solutions through our private label program”, said Paul Pedersen, CEO of the Company.

Nextleaf plans to seek patent protection around the Acquired IP and to develop a new patent family. The Company currently has a pending to issued patent allowance success rate of 100% (i.e. the Company has never received a final rejection from any patent office globally) compared with a cannabis sector average of less than 30%, with 12 issued patents related to the industrial-scale extraction and purification of cannabinoids.

The Company remains committed to developing and monetizing its intellectual property portfolio through IP licensing, and supplying THC and CBD oils under private label through Nextleaf Labs, a Health Canada licensed Standard Processor. The Company started generating licensing royalties in 2019 from its previously announced agreement to license non-core IP.

“For the past three years our team has focused on developing efficient, patented extraction technology to put distilled cannabinoids into IP-protected delivery formats such as beverages and edibles.” said Pedersen.

The developers behind the Acquired IP combine expert chemical engineering with tenured experience from one of the largest Canadian dairy product manufacturers. By meeting the second and final milestone defined in the agreement, Nextleaf will issue the developers 937,500 Nextleaf common shares at a price of $0.32 per share.

About Nextleaf Solutions
OILS is developing disruptive intellectual property for extraction, purification, and formulation of cannabinoids. The Company owns a portfolio of 12 issued patents pertaining to the industrial-scale production of high-purity, cannabinoid-rich distillate, the key ingredient used in the manufacturing of standardized THC and CBD based products. Nextleaf Solutions commercializes its intellectual property portfolio through IP licensing, and supplying THC and CBD oils through Nextleaf Labs, a Health Canada licensed Standard Processor.

Nextleaf Solutions trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market in the United States, and L0MA on the Frankfurt Stock Exchange.

Click here to connect with Nextleaf Solutions Ltd. (CSE:OILS, OTCQB:OILFF, Frankfurt:L0MA) for an Investor Presentation

Source

Fundraising, Subscription by Directors and Love Hemp Q1 Trading Update

World High Life Plc (“World High Life” or the “Company”) (AQSE:LIFE) (OTCQB:WRHLF) announces that it has raised £566,206 via the issue of 56,620,600 ordinary shares of 1 pence each in the Company (“Ordinary Shares”; the “Subscription Shares”) at a subscription price of 1.0p per share. The proceeds of the Subscription Shares will be used by the Company for general working capital purposes

Keep reading... Show less

Global Wellness Strategies Inc. (formerly Redfund Capital Corp.) (CSE: LOAN) (FSE: O3X4) (OTCQB: PNNRD) (“Global” or the “Company”) announces it has signed a binding letter of intent (“BLOI”) on January 22, 2021 with EntheoTech Bioscience Inc. (“ET”) a wellness psilocybin leader based in Kelowna, British Columbia and will have the option to earn up to a 19.9% interest in ET.

EntheoTech is a Canadian bioscience company focused on the research and development of products, and protocols to promote brain health, performance optimization, and global wellness, using psychoactive substances such as psilocybin, medicinal mushrooms, and other natural products.

Keep reading... Show less

The new dispensary brings expanded access for patients along Florida’s Atlantic Coast

Trulieve Cannabis Corp. (CSE: TRUL)  (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 78th nationwide. The new 4,600 sq. ft. location marks the Company’s first in the city of Sebastian and second in Indian River county expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal 2021 ended December 31, 2020 before financial markets open on February 9, 2021.

Keep reading... Show less

NYSE | TSX: ACB

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Keep reading... Show less